-

Arrival SA Shareholder Alert: Robbins LLP Reminds Investors that Arrival SA (ARVL, ARVLW) is Being Sued for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired common shares of Arrival SA (NASDAQ: ARVL, ARVLW) between November 18, 2020 and November 19, 2021, for violations of the Securities Exchange Act of 1934. Arrival manufactures and distributes commercial electric vehicles (EVs), including vans, cars, and buses.

If you suffered a loss due to Arrival SA's misconduct, click here.

Arrival SA (ARVL, ARVLW) Misled Investors Regarding its Business Prospects

According to the complaint, on March 24, 2021, Arrival combined with CIIG Merger Corp., a special purpose acquisition corporation, and began trading under the symbols ARVL and ARVLW on March 25, 2021. During the class period, defendants purportedly failed to disclose that: (i) the Company would record a substantially greater net loss and adjusted EBITDA loss in the third quarter 2021 compared to third quarter 2020; (ii) would experience far greater capital and operational expense to operate and deploy its microfactories and EV vehicles than it had disclosed; and (iii) would not achieve profitability or provide meaningful revenue in the time periods disclosed. Further, defendants failed to disclose that the Company would not achieve its disclosed production and sales volume or its production rollout deadlines.

The truth came out in a series of disclosures beginning on November 8, 2021. On that date, Arrival announced its financial results for the third quarter 2021, including a loss of €26 million (compared to a loss of €22 million during the same quarter a year earlier), and adjusted EBITDA loss for the quarter of €40 million (compared to a loss of €18 million in the third quarter of 2020). The Company also pulled its 2022 revenue goals and scaled back its long-term projections, pushing its production and sales timeline into later time periods. On this news, Arrival shares plummeted 24%, to close at $13.46 on November 10, 2021.

Then, on November 17, 2021, Arrival announced a $200 million offering of green convertible senior notes due 2026, intended to finance the development of EVs. On the same day, Arrival announced the commencement of an underwritten public offering of 25 million ordinary shares intended to raise around $330 million. On this news, Arrival shares dropped approximately 8%, to close at $9.91 per share on November 18, 2021, harming investors.

If you purchased shares of Arrival SA (ARVL, ARVLW) between November 18, 2020 and November 19, 2021, you have until February 22, 2022, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Arrival SA settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom